LAWRENCE, Mass., Oct. 26, 2018 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, today announced that the
number of home hemodialysis (HHD) patients using its Nx2me
Connected Health platform has increased 220% in the past
year.1
Nx2me® is designed to enhance the connection
between NxStage® System One™ HHD patients
and clinicians, and has been shown to improve patient retention and
training graduation rates. Research findings demonstrate that
patients using Nx2me experienced:
- 29% lower therapy discontinuation rates due to controllable
causes,2 and,
- 34% reduction in technique failure, relative to match controls
in patients who began using Nx2me within 3 months of initiating
HHD.2
"We are really beginning to see a shift toward using innovative
telehealth solutions to help improve patient outcomes with home
dialysis," said Dr. Michael
Kraus, Associate Chief Medical Officer for NxStage. "Nx2me
is an intuitive tool to support and proactively engage with home
hemodialysis patients. The platform's impressive performance data
will continue to inform and influence home dialysis programs,
ultimately helping more patients succeed on home hemodialysis."
A key component of the Nx2me platform is the Nx2me
iPad® app, which is designed to increase patients' ease
of use of home therapy by capturing treatment data and wirelessly
sending it to their center after each treatment, thereby reducing
the need for paper flow sheets. Dialysis center staff can access
the treatment data, sent through a secured and encrypted web
server, using the Nx2me Clinician Portal. The timely receipt of
electronic flowsheets from the Nx2me app allows for early
intervention to help reduce patient complications and
hospitalizations. In addition, Nx2me integrates with center EMR
systems to provide clinicians with treatment and billing
information.
NxStage continues to enhance the capabilities of the Nx2me
platform, introducing new features including picture sharing
between patients and clinicians, and streaming video to enhance
communication with NxStage Technical Support.
For more information about Nx2me and home hemodialysis with the
NxStage System One, please visit www.NxStage.com.
The reported benefits of home hemodialysis (HHD) may not be
experienced by all patients.
The NxStage System is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
When vascular access is exposed to more frequent use, infection of
the site, and other access related complications may also be
potential risks. The medical devices used in hemodialysis
therapies may add additional risks including air entering the
bloodstream, and blood loss due to clotting or accidental
disconnection of the blood tubing set.
Home hemodialysis with the NxStage System during waking hours
may not require a care partner, provided a physician and a
qualified patient agree that solo home hemodialysis is appropriate.
Patients performing nocturnal treatments are required to have a
care partner. Care partners are trained on proper operation and how
to get medical or technical help if needed.
Certain risks associated with hemodialysis treatment are
increased when performing solo HHD because no one is present to
help the patient respond to health emergencies. If patients
experience needles coming out, blood loss, or very low blood
pressure during solo HHD, they may lose consciousness or become
physically unable to correct the health emergency. Losing
consciousness or otherwise becoming impaired during any health
emergency while alone could result in significant injury or death.
Additional ancillary devices and training are required when
performing solo HHD.
Certain risks associated with hemodialysis treatment are
increased when performing nocturnal therapy due to the length of
treatment time and because therapy is performed while the patient
and care partner are sleeping. These risks include, but are not
limited to, blood access disconnects and blood loss during sleep,
blood clotting due to slower blood flow and/or increased treatment
time, and delayed response to alarms when waking from
sleep.
Patients should consult their doctor to understand the risks
and responsibilities of performing these therapies using the
NxStage System.
About the NxStage System One
The NxStage System
One is a simple, flexible and portable hemodialysis system that
provides a wide range of dialysis therapy options, including home,
more frequent, solo, and nocturnal dialysis.
Visit www.nxstage.com for more information on therapy
options with the System One.
About NxStage Medical
NxStage Medical, Inc.
(Nasdaq: NXTM) is a leading medical technology company,
headquartered in Lawrence, MA,
that develops, manufactures and markets innovative products for the
treatment of ESRD and acute kidney failure. For more information on
NxStage and its products and services, please visit the Company's
website at www.nxstage.com.
Forward-looking Statements
This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this release that are not clearly historical in nature
are forward-looking, and the words "anticipate," "believe,"
"expect," "estimate," "plan," and similar expressions are generally
intended to identify forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors including those
that are discussed in NxStage's filings with the Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended June 30, 2018.
NxStage is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
References:
1. Data on file. 2018. NxStage Medical, Inc.
2. Weinhandl E, Collins AJ. Relative risk of home hemodialysis
attrition in patients using a telehealth platform. Hemodial
Int. 2018;22(3):318-327.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nxstage-announces-significant-increase-in-nx2me-connected-health-platform-adoption-300738675.html
SOURCE NxStage Medical, Inc.